Shaker Investments LLC OH Takes $532,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Shaker Investments LLC OH purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,920 shares of the company’s stock, valued at approximately $532,000.

Several other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in Krystal Biotech by 23.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock valued at $28,292,000 after purchasing an additional 43,709 shares during the last quarter. Vanguard Group Inc. grew its stake in Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Krystal Biotech by 6.6% in the first quarter. Los Angeles Capital Management LLC now owns 10,214 shares of the company’s stock valued at $1,817,000 after purchasing an additional 629 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in Krystal Biotech by 5.6% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 33,154 shares of the company’s stock valued at $5,899,000 after purchasing an additional 1,756 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in Krystal Biotech by 167.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 158,425 shares of the company’s stock valued at $28,189,000 after purchasing an additional 99,101 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on KRYS shares. Chardan Capital raised their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. HC Wainwright raised their price target on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Evercore ISI raised their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $196.75.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Up 3.2 %

Krystal Biotech stock opened at $178.71 on Friday. Krystal Biotech, Inc. has a 52 week low of $93.95 and a 52 week high of $219.34. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 95.57 and a beta of 0.82. The stock has a 50-day moving average price of $186.77 and a 200 day moving average price of $180.03.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the previous year, the company posted ($1.25) earnings per share. The company’s revenue was up 70283900.0% compared to the same quarter last year. Research analysts anticipate that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).